2:41 PM
Jun 13, 2019
 |  BC Innovations  |  Emerging Company Profile

Gracell: Speeding up CAR T cells

Gracell's manufacturing platform could accelerate production of CAR T cell therapies from two weeks to one day

With a platform that could reduce the manufacturing time of autologous CAR T cells from two weeks to one day, Gracell is lining up a set of therapies it could produce with the method.

Gracell Biotechnologies Co. Ltd. founder, Chairman and CEO William Cao told BioCentury that the company, which emerged from stealth in February with a $85 million series B round led by Temasek, plans to address the lengthy production times and high costs of CAR T cell therapies.

Conventional CAR T cell manufacturing -- which involves genetic modification of patient-derived T cells, and activation and expansion of the T cells -- takes around two weeks, said Cao. Regulator-required lot-release testing can add an additional seven days to the "vein-to-vein" time for autologous CAR T therapies.

The company’s FasT CAR T platform manufactures therapies overnight, returning the therapies to the hospital the day after receiving patient cells.

"Leukemia cells double in the blood every day, so for this obvious, simple reason you want the drug to get into the blood and start to kill the leukemia cells immediately," said Cao. Because...

Read the full 899 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >